Viridian Therapeutics/$VRDN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Ticker
$VRDN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
143
Website
VRDN Metrics
BasicAdvanced
$1.4B
-
-$3.33
0.45
-
Price and volume
Market cap
$1.4B
Beta
0.45
52-week high
$25.21
52-week low
$9.90
Average daily volume
700K
Financial strength
Current ratio
19.487
Quick ratio
18.876
Long term debt to equity
3.734
Total debt to equity
3.822
Interest coverage (TTM)
-110.67%
Profitability
EBITDA (TTM)
-336.492
Gross margin (TTM)
-78,484.11%
Net profit margin (TTM)
-102,092.38%
Operating margin (TTM)
-111,590.73%
Management effectiveness
Return on assets (TTM)
-32.62%
Return on equity (TTM)
-51.95%
Valuation
Price to revenue (TTM)
4,232.906
Price to book
3.44
Price to tangible book (TTM)
3.44
Price to free cash flow (TTM)
-4.559
Free cash flow yield (TTM)
-21.94%
Free cash flow per share (TTM)
-3.843
Growth
Revenue change (TTM)
4.86%
Earnings per share change (TTM)
15.17%
3-year revenue growth (CAGR)
-44.09%
3-year earnings per share growth (CAGR)
-13.43%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Bulls say / Bears say
Viridian Therapeutics' lead drug candidate, veligrotug (formerly VRDN-001), demonstrated promising efficacy and safety in treating thyroid eye disease (TED), with potential to become the preferred intravenous treatment option upon commercial availability. (businesswire.com)
The company initiated pivotal development for VRDN-003, a subcutaneous autoinjector form of veligrotug, aiming to capture a significant share of the TED market with this innovative treatment option. (businesswire.com)
Viridian completed a public offering in September 2024, raising approximately $225 million, bolstering its financial position to fund ongoing clinical development and potential commercialization efforts. (businesswire.com)
Viridian reported a net loss of $76.7 million for the third quarter ended September 30, 2024, compared to a net loss of $47.7 million for the same period last year, indicating increasing operational expenses. (businesswire.com)
The company's revenue for the quarter ended September 2024 was $0.09 million, surpassing estimates but highlighting the early-stage nature of its product pipeline with minimal current revenue generation. (nasdaq.com)
Viridian's stock has experienced significant volatility, with a year-to-date decline of nearly 25% as of March 2025, reflecting investor concerns over financial performance and market competition. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
VRDN News
AllArticlesVideos
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
Business Wire·2 days ago
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viridian Therapeutics stock?
Viridian Therapeutics (VRDN) has a market cap of $1.4B as of August 01, 2025.
What is the P/E ratio for Viridian Therapeutics stock?
The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of August 01, 2025.
Does Viridian Therapeutics stock pay dividends?
No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Viridian Therapeutics dividend payment date?
Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.
What is the beta indicator for Viridian Therapeutics?
Viridian Therapeutics (VRDN) has a beta rating of 0.45. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.